New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition

New Data from Luspatercept Phase 2 Clinical Trial in Beta-Thalassemia Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition

December 7, 2014

SUMMIT, N.J. & CAMBRIDGE, Mass.--()--Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc.

Pronutria Adds Industry Leaders to its Board of Directors

Pronutria Adds Industry Leaders to its Board of Directors

December 8, 2014

CAMBRIDGE, Mass., Dec. 8, 2014 /PRNewswire/ -- Pronutria Inc., which is developing novel oral biologics to restore cellular homeostasis in a range of serious medical conditions, announced today that industry veterans Peter Barton Hutt, Senior Counsel at Covington & Burling and former chief counsel of the FDA; Dr. Stephen Hoge, Senior Vice President, Corporate Development and New Drug Concepts for Moderna Therapeutics; and Dr. John Mendlein, Executive Chairman and CEO of aTyr Pharma and former CEO of Adnexus Therapeutics, have joined the Board of Directors.

Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016

Agios Announces Celgene Decision to Extend Discovery Phase of Global Strategic Collaboration to April 2016

December 8, 2014

CAMBRIDGE, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that Celgene Corporation has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform.

Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies

Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies

December 7, 2014

Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers

Company Expects Global Registration Program to Begin for IDH2 inhibitor AG-221 in 2015 and IDH1 inhibitor AG-120 by early 2016 Agios Announces 2015

Upcoming Milestones for IDH Programs

Pronutria Appoints Dr. Peter Mueller as President of R&D and Chief Scientific Officer

Pronutria Appoints Dr. Peter Mueller as President of R&D and Chief Scientific Officer

December 4, 2014

CAMBRIDGE, Mass., Dec. 4, 2014 /PRNewswire/ -- Pronutria Inc., which is developing novel oral biologics to restore cellular homeostasis in a range of serious medical conditions, announced today that Peter Mueller, Ph.D., has been appointed President of Research and Development and Chief Scientific Officer.  Dr.

TIME's Best Inventions List Also Includes an Edible Invention from Cambridge

TIME's Best Inventions List Also Includes an Edible Invention from Cambridge

November 24, 2014

These foods aren't just convenient and crave-worthy - they could also shrink our environmental footprint.

Last week, TIME published a list of the Best Inventions of 2014 - and while we already covered three noteworthy local companies, we missed a genius gastronomical creation that also happens to hail from Boston.

Seres Health Closes $48 Million Series C Financing

Seres Health Closes $48 Million Series C Financing

December 2, 2014

CAMBRIDGE, Mass., Dec. 2, 2014 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, announced today that it has closed its Series C round with $48 million in new investment.

Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital

Editas Medicine Licenses Genome Editing Technology from Massachusetts General Hospital

December 1, 2014

Exclusive Agreement Provides Access to Intellectual Property and Technology for a Broad Range of Therapeutic and Agricultural Applications

Editas Medicine Licenses Genome Editing Technology from Duke University

Editas Medicine Licenses Genome Editing Technology from Duke University

December 1, 2014

Exclusive Agreement Provides Access to Intellectual Property and Technology for the Development of Human Therapeutics  

Broad Institute, Harvard, And MIT License CRISPR-Cas9 Technology To Editas Medicine For Therapeutic Applications

Broad Institute, Harvard, And MIT License CRISPR-Cas9 Technology To Editas Medicine For Therapeutic Applications

December 1, 2014

STRATEGIC AGREEMENT ALLOWS FOR ADDITIONAL THERAPEUTIC LICENSING ON A GENE-BY-GENE BASIS

BOSTON and CAMBRIDGE, Mass., Dec. 1, 2014 /PRNewswire-USNewswire/ -- The Broad Institute, Harvard University, the Massachusetts Institute of Technology and Editas Medicine have entered into a worldwide license agreement to grant Editas access to intellectual property related to certain genome editing technology for the development of human therapeutic applications.